Discovery and characterization of benzyloxy piperidine based dopamine 4 receptor antagonists was written by Tolentino, Kirsten T.;Mashinson, Viktoriya;Vadukoot, Anish K.;Hopkins, Corey R.. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2022.SDS of cas: 58442-17-4 This article mentions the following:
The dopamine receptor 4 (D4R) is highly expressed in both motor, associative and limbic subdivisions of the cortico-basal ganglia network. Due to the distribution in the brain, there is mounting evidence pointing to a role for the D4R in the modulation of this network and its subsequent involvement in L-DOPA induced dyskinesias in Parkinson′s disease. As part of our continued effort in the discovery of novel D4R antagonists, we report the discovery and characterization of a new 3- or 4-benzyloxypiperidine scaffold as D4R antagonists. We report several D4R selective compounds (>30-fold vs. other dopamine receptor subtypes) with improved in vitro and in vivo stability over previously reported D4R antagonists. In the experiment, the researchers used many compounds, for example, 1H-Benzimidazole-5-carbaldehyde (cas: 58442-17-4SDS of cas: 58442-17-4).
1H-Benzimidazole-5-carbaldehyde (cas: 58442-17-4) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. SDS of cas: 58442-17-4
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem